deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03317899

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

A Randomized Controlled Trial Evaluating the Use of G-CSF After Plerixafor-Mobilized Autologous Stem Cell Transplant (Auto HSCT)

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Conditions Non-Hodgkin's Lymphoma Plasma Cell Myeloma
Interventions Hematopoietic Cell Transplantation Laboratory Biomarker Analysis Tbo-filgrastim
Updated 12 times since 2017 Last updated: Nov 21, 2025 Started: Oct 12, 2017 Primary completion: Jun 1, 2021 Completion: Nov 16, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-Hodgkin's Lymphoma and Plasma Cell Myeloma, this trial is completed. The trial is conducted by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University and has accumulated 12 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshotNot Yet Recruiting~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotRecruiting~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshotRecruiting~Jun 2019 – ~Jul 2020 · 13 months · monthly snapshotRecruiting~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshotRecruiting~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotRecruiting~Oct 2021 – ~Dec 2022 · 14 months · monthly snapshotActive Not Recruiting~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Jan 2026 · 16 months · monthly snapshotCompleted~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshotCompleted~Feb 2026 – present · 6 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

  2. Jan 2026 — Feb 2026 [monthly]

    Completed PHASE2

  3. Sep 2024 — Jan 2026 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 7 earlier versions

  1. Oct 2021 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  3. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Jun 2019 — Jul 2020 [monthly]

    Recruiting PHASE2

  5. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  6. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Nov 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Oct 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations